This study aims at for the first time investigating the links between copeptin concentration and fatty liver disease, as knowledge of the underlying causes of NAFLD is a prerequisite for the identification of more specific lifestyle and pharmacological treatment. The gene discussed is AVP; the disease is metabolic dysfunction-associated steatotic liver disease.